/ Sun Pharma, Samsung BioLogics Tie Up To Manufacture Tildrakizumab ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Tuesday, 4 July 2017

There is a strategic long term manufacturing agreement for Tiladrakizumab between the Sun Pharmaceutical Industries Ltd and Samsung BioLogics which has entered into them.

The approximate value of the contract is USD 55.5 million. The agreement by the Sun Pharmaceutical is a wholly owned subsidiary and the Samsung BioLogics.

Sun pharma appointed Samsung BioLogics for the manufacturing Tiladrakizumab for the investigate IL-23p19 inhibitor is for the treatment of the moderate severe plaque psoriasis.

It has been accepted for review by the USFDA in May and in the March 2017 European Agency (EMA).

On BSE Monday trading the stock is also opened in green rating and its gaining 0.45% at Rs.554.95 per share.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.co
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔
Give a Missed Call for Free Trial - 09699997717 ✔